1. Home
  2. REAL vs DVAX Comparison

REAL vs DVAX Comparison

Compare REAL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The RealReal Inc.

REAL

The RealReal Inc.

HOLD

Current Price

$14.10

Market Cap

1.4B

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.90

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAL
DVAX
Founded
2011
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
REAL
DVAX
Price
$14.10
$10.90
Analyst Decision
Buy
Buy
Analyst Count
8
4
Target Price
$13.94
$26.50
AVG Volume (30 Days)
4.7M
1.9M
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$662,789,000.00
$330,514,000.00
Revenue This Year
$14.56
$23.23
Revenue Next Year
$10.14
$16.57
P/E Ratio
N/A
N/A
Revenue Growth
14.30
26.73
52 Week Low
$4.61
$9.20
52 Week High
$16.24
$14.63

Technical Indicators

Market Signals
Indicator
REAL
DVAX
Relative Strength Index (RSI) 57.87 50.60
Support Level $13.84 $10.63
Resistance Level $14.89 $11.58
Average True Range (ATR) 0.88 0.32
MACD -0.03 -0.05
Stochastic Oscillator 42.28 30.00

Price Performance

Historical Comparison
REAL
DVAX

About REAL The RealReal Inc.

The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: